DOI: 10.1055/s-00000094

Zeitschrift für Gastroenterologie

References

Kulke MH. et al.
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differenziated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.

Ann Oncol 2017;
28: 1309-1315

Download Bibliographical Data

Search in:
Access: